{"id":"NCT02394795","sponsor":"Takeda","briefTitle":"Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC","officialTitle":"A Phase III, Randomized, Controlled Study of mFOLFOX6 + Bevacizumab Combination Therapy Versus mFOLFOX6 + Panitumumab Combination Therapy in Chemotherapy-naive Patients With KRAS/NRAS Wild-type, Incurable/Unresectable, Advanced/Recurrent Colorectal Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-05-29","primaryCompletion":"2022-01-14","completion":"2022-01-14","firstPosted":"2015-03-20","resultsPosted":"2023-11-01","lastUpdate":"2023-11-01"},"enrollment":823,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Colorectal Cancer"],"interventions":[{"type":"DRUG","name":"oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab","otherNames":[]},{"type":"DRUG","name":"oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab","otherNames":[]}],"arms":[{"label":"Group P; mFOLFOX6 + panitumumab combination therapy","type":"EXPERIMENTAL"},{"label":"Group B; mFOLFOX6 + bevacizumab combination therapy","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to verify the efficacy of mFOLFOX6 + panitumumab combination therapy and mFOLFOX6 + bevacizumab combination therapy in first-line treatment of chemotherapy-naive patients with KRAS/NRAS wild-type, incurable/unresectable, advanced/recurrent colorectal cancer.","primaryOutcome":{"measure":"OS in Participants With Left-sided Tumors","timeFrame":"Up to approximately 60 months","effectByArm":[{"arm":"Group P; mFOLFOX6 + Panitumumab Combination Therapy","deltaMin":37.85,"sd":null},{"arm":"Group B; mFOLFOX6 + Bevacizumab Combination Therapy","deltaMin":34.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":155,"countries":["Japan"]},"refs":{"pmids":["38347302","37071094","28237539"],"seeAlso":["https://clinicaltrials.takeda.com/study-detail/5f6b60294db2bf003ab499d1"]},"adverseEventsSummary":{"seriousAny":{"events":115,"n":404},"commonTop":["Peripheral sensory neuropathy","Neutrophil count decreased","Decreased appetite","Stomatitis","Fatigue"]}}